Macquarie Group LTD Immunovant, Inc. Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in Immunovant, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 185,984 shares of IMVT stock, worth $5.12 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

185,984

Previous 122,100 52.32%

Holding current value

$5.12 Million

Previous $3.22 Million 58.73%

% of portfolio

0.01%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $1.76 Million - $1.76 Million	63,884 Added 52.32%	185,984 $5.12 Million
Q2 2024 Aug 09, 2024	BUY	$25.1 - $31.61 $476,900 - $600,590	19,000 Added 18.43%	122,100 $3.22 Million
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $1.89 Million - $2.74 Million	62,474 Added 153.78%	103,100 $3.33 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $1.27 Million - $1.8 Million	40,626 New	40,626 $1.71 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $3,839 - $6,223	-977 Reduced 80.08%	243 $7,000
Q4 2021 Feb 11, 2022	SELL	$7.33 - $9.32 $20,545 - $26,123	-2,803 Reduced 69.67%	1,220 $10,000
Q3 2021 Nov 12, 2021	SELL	$7.01 - $11.37 $352,960 - $572,490	-50,351 Reduced 92.6%	4,023 $35,000
Q2 2021 Aug 13, 2021	BUY	$9.4 - $16.85 $31,339 - $56,177	3,334 Added 6.53%	54,374 $575,000
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $392,138 - $1.49 Million	29,980 Added 142.36%	51,040 $819,000
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $58,103 - $84,230	-1,598 Reduced 7.05%	21,060 $973,000
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $491,925 - $846,347	21,757 Added 2414.76%	22,658 $798,000
Q2 2020 Aug 11, 2020	SELL	$13.87 - $28.44 $31,998 - $65,611	-2,307 Reduced 71.91%	901 $22,000
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $26,818 - $54,953	3,208 New	3,208 $50,000

Others Institutions Holding IMVT

# of Institutions

212

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Immunovant, Inc. Transaction History